OOIR: Observatory of International Research

Papers

(The median citation count of Lung Cancer is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis	127
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England	99
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients	95
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy	90
175 External Validation of a Left Anterior Descending Coronary Artery Dose Constraint in Patients with Non-Small Cell Lung Cancer: An NI–HEART Analysis	72
190 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status	67
251 Optimising engagement and addressing inequalities for patients using a Digital Behaviour Change Intervention in lung cancer prehabilitation: A mixed-methods study	65
260 Second Primary Lung Cancer Cohort Study (SPORT)	59
101 Treating advanced EGFR positive non-small cell lung cancer patients with Osimertinib - the University Hospital Plymouth experience	56
107 Osimertinib Efficacy in Advanced NSCLC Patients with PACC and Classical-Like EGFR Mutations: A Retrospective Analysis from The Christie	55
98 Hospitalisation Rates following Systemic Anti-Cancer Treatments for Patients with Non-Small Cell Lung Cancer	54
74 The first-in-class PRX3 inhibitor RSO-021 modulates the composition of malignant pleural effusions by eliciting immunomodulation and decreasing epithelial to mesenchymal protein expression	52
86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer	48
89 Why do almost half of our patients not complete 12 months of maintenance durvalumab after successful radical chemoradiotherapy?	46
Contents	44
Title Page	44
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma	43
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study	41
The first historical description of malignant mesotheliomas	41
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study	39
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes	39
Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study	37
Spatial microenvironment heterogeneity in therapy-naïve lung cancer: A concept with more attention needed	37
The role of mediastinoscopy following EBUS	37
Author index	37

Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent	36
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers	35
Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting	35
Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC	35
Indwelling pleural catheter infections: a cautionary tale	34
Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma	33
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry	33
Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1	31
Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study	31
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer	31
Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy	30
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib	30
Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas	30
Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer	29
RET Fusion–Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy	29
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial	29
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer	29
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide	28
APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma	28
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study	28
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis	28
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer	27
Patient-reported EORTC QLQ C-30 global health status decline predicts survival after video-assisted thoracoscopic (VATS) lung resection and stereotactic ablative radiotherapy (SABR): A 5 year follow-u	27
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion	27
Cell pellet from fixative medium of transbronchial lung biopsy sample improves lung cancer ancillary test	27
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer	27
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial	26
Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer	26
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score	26
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the	26
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial	26
Evaluating lung cancer risk factors in adults with interstitial lung disease	26
144 SIPS-NLR Predicts Overall Survival in Patients with Advanced NSCLC Receiving First-Line Chemo-Immunotherapy	25
Neighborhood matters: Predicting lung cancer screening adherence with explainable AI	25
WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors	25
Corrigendum to “Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)” [Lung Cancer 210 (2025) 108840]	25
35 Feasibility and optimisation of day-case Microwave Lung Ablation in small intrathoracic malignancies: A Five-Year Retrospective Analysis and pilot study	24
Editorial Board	24
248 Screening 100: Early-Stage Lung Cancer Detection Following Full Population Invitation Roll-Out of Lung Cancer Screening in North Central London	24
127 Pembrolizumab Monotherapy for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (NSCLC): 10-Year Outcomes From Clinical Trials	23
22 Treatment Ineligibility in Stage IV Non-Small Cell Lung Cancers Following Invasive Investigations: Clinical Characteristics and Outcomes	23
119 Simple Biomarker Predicts Receipt of Adjuvant Immunotherapy after Concurrent Chemoradiation for Non-Small Cell Lung Cancer	23
201 The Integration of Body Composition with NLR Improves Prognostic Modelling in Lung and Oesophageal Cancer	22
38 Prehabilitation for Patients Undergoing Radical Radiotherapy for Lung Cancer	22
125 Concurrent chemoradiotherapy for inoperable NSCLC in an aging population - is it safe over seventy?	22
Lung cancer incidence in counties at low and high risk of Radon Exposure: A Population-Based SEER analysis (1975–2022)	22
82 CT Guided Biopsy versus Electromagnetic Navigational Bronchscopy for Peripheral Pulmonary Nodules - Real-world UK experience	22
135 Outcomes of patients with advanced non-small cell lung cancer (aNSCLC) enrolled in early phase clinical trials: a 10-year analysis from the Sarah Cannon Research Institute (SCRI) UK Drug Developme	22
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study	21
31 The Nodules of Norfolk, Setting up a Pulmonary Nodule Pathway in a secondary care setting at the Norfolk & Norwich University Hospital – A reflective study over one year from January 2023 – Jan	21

60 First-line Nivolumab/Ipilimumab in patients with unresectable malignant pleural Mesothelioma (MPM): West of Scotland experience	21
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study	21
143 Comparative Evaluation of Clinical Frailty Scale and WHO Performance Status For Predicting 90-day and One-year Mortality in People with Lung Cancer	21
69 New research-based resources to facilitate engagement with palliative care for patients and families living with mesothelioma	21
37 Diagnostic performance across two high-volume EBUS services in Greater Manchester with and without Rapid On-Site Evaluation (ROSE)	21
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival	21
22 Challenges in Meeting Molecular Testing Turnaround Times in Lung Cancer	21
67 The mental health and well-being implications of a mesothelioma diagnosis: a mixed methods study	21
219 “Fewer than 100 cigarettes in lifetime” deemed low risk for lung cancer – should we continue to offer Lung cancer screening to this cohort	20
135 The Impact of the Electronic Patient Record on Completion and Uploading of the Holistic Needs Assessment in Lung Cancer patients	20
95 Lorlatinib in advanced ALK-rearranged NSCLC – real-world experience in a UK population	20
195 The impact of measured versus estimated height and weight on lung cancer screening eligibility – analysis from the Yorkshire Lung Screening Trial	20
206 Screening benefits and harms; a review of false positives and negatives from the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Targeted Lung Health Check (TLHC) programme	20
204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design	20
186 Lung cancer and mental health: experiences reported by UK patients and carers	19
Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer	19
23 A review of follow-up imaging for surgically treated lung cancer patients. Can the pathway be optimised further?	19
Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis	19
Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer	19
Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting	19
147 Review of patients with metastatic and locally advanced NSCLC who receive 2 years of palliative pembrolizumab with or without chemotherapy	18
308 SMARCA4-deficient large-cell neuroendocrine carcinoma of the lung with concurrent TP53 and RB1 loss; a molecularly unique case	18
80 A Review into Local Rates and Management of Pneumothorax post-CT Guided Lung Biopsy at a District General Hospital in England	18
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial	18
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART	18
313 Osimertinib tolerance and sustained disease control in recurrent squamous cell lung cancer with rare compound EGFR mutations (G719A and H773L)	18
112 The role of family carers in mesothelioma end-of-life in the UK	18
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities	18
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)	18
257 Introducing a rapid pathway for suspected small cell lung cancer: Greater Manchester Cancer Alliance experience	18
279 Surgical Extent in Screening-Detected Lung Cancer: Lobectomy vs Sublobar Resection	18
110 Experience of ipilimumab/nivolumab treatment for malignant mesothelioma (MM): results from a large tertiary centre	18
Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy	18
Contents	18
Initial experience of CT guided percutaneous microwave ablation of lung metastasis in a district general hospital	17
Assessing the impact of the pharmacist independent prescriber as part of the multi-disciplinary care of patients receiving adjuvant treatment for NSCLC	17
Two years on: progression free survival analysis of patients with advanced small cell lung cancer receiving atezolizumab plus etoposide and carboplatin in a tertiary oncology centre	17
Contents	17
Rethinking continuity in primary care for people with mesothelioma	17
The impact of real-world lung cancer screening programmes on downstream diagnostic capacity	17
Contents	17
Contents	17
Impact and causes of readmission within 90-days of non-small cell lung cancer surgery	17
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real–world	16
Contents	16
A combined model of circulating tumor DNA methylated SHOX2/SCT/HOXA7 and clinical features facilitates the discrimination of malignant from benign pulmonary nodules	16
11 Making an accurate diagnosis of anterior mediastinal lesions: A proposal for a new diagnostic algorithm from the BTOG Thymic Interest Group	16
Analyzing diagnostic and treatment wait times for lung cancer Patients: Key insights from a provincial registry study	16
Improving the use of NOACS for cancer-related VTE in Great Western Hospital	16
Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma	16
Prognostic impact of extracapsular extension of lymph nodes in resected lung cancer: analysis by new N subcategories and histologic types	16
Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies	16
CAR-T cell therapy for the treatment of lung cancer: Current challenges and emerging therapeutic strategies	16
Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment	16
Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor	15
93 A regional-West Midlands audit on implementing the neo-adjuvant chemoimmunotherapy (NACIO) pathway for resectable non-small cell Cancer (NSCLC) patients	15
193 The Impact of a Targeted Lung Health Check Program on Oncology Services at UHCW	15
198 Pilot lung screening in Scotland: intervention findings and qualitative insights	15
Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer	15
Commentary on: Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning	15
70 Trial protocol and update for the DREM study	15
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis	15
109 Alk-positive NSCLC: Side effects - the real-world experiences of UK patients	15
Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients	15
56 High Frequency Jet Ventilation assisted CT guided lung biopsy service in a district general hospital	15
173 Real world outcomes for patients receiving radical radiotherapy for stage 3 Non-Small Cell Lung Cancer post-PACIFIC	15
Contents	15
Perceived barriers to curative treatment for patients with early stage lung cancer: a mixed methods study	14
Understanding the mental health and well-being impacts and interventions related to living with mesothelioma: a systematic review	14
Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis	14
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking	14
Immunogenicity of COVID-19 vaccines in lung cancer patients	14
Editorial Board	14
Research on the road: taking lung cancer research to the patient	14
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study	14
Construction and validation of a clinical differentiation model between peripheral lung cancer and solitary pulmonary tuberculosis	14
Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma	14
Endobronchial ultrasound–transbronchial nodal aspiration (EBUS-TBNA) with rapid on-site evaluation (ROSE) in the Ulster Hospital, 2021	14
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation	14
157 Establishing a multidisciplinary habilitation clinic for lung cancer patients receiving radical radiotherapy	14

128 90 day admissions and mortality in lung cancer patients	13
54 A population-based review of early-onset lung cancer patients in Northern Ireland	13
Corrigendum to “Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trial	13
Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations	13
A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR mutation status of small sized lung cancers with difficulty to measure the diameter of solid component in part-solid tumor	13
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)	13
77 Toxicity and outcomes for patients with resected Non-Small cell lung cancer (NSCLC) who have received adjuvant chemotherapy in Bristol	13
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study	13
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study	13
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison	13
Real-world occurrence of severe gastrointestinal bleeding in patients receiving amivantamab plus lazertinib: A two-case series among 25 consecutive cases	13
Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib	13
46 Automated Derivation of Diagnostic Criteria for Lung Cancer using Natural Language Processing on Electronic Health Records: A pilot study	13
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma	13
169 Can reminders improve lung cancer screening uptake amongst higher-risk populations?	13
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study	13
Immunotherapy in uncommon EGFR-mutant NSCLC: Revisiting a therapeutic gray zone	13
Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram	12
168 Identifying the Need for Specialist Occupational Intervention for Thoracic Cancer Patients Experiencing Poor Quality Sleep	12
202 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status	12
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations	12
251 The use of Carboplatin, Etoposide and Atezolizumab in Small Cell Lung cancer: A single centre study, Leeds, UK	12
203 Chemoradiation (CRT) in Non-Small Cell Lung cancer (NSCLC) – Local experience and comparison with PACIFIC-R real world data	12
Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma	12
Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial	12
KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence	12
222 Referrals to Screening Review meeting within Greater Manchester Lung Cancer screening	12
114 Exploring patient experiences of proton beam therapy within the HIT-MESO trial: a qualitative sub-study	12
307 From inoperable to operable: the impact of prehabilitation in advanced lung cancer	12
151 Real-world prognostic value of ePROMs in first-line osimertinib for EGFR-mutant NSCLC: a single-centre cohort	12
278 The diagnostic challenges of cartilaginous tumours of the thorax	12
236 The Good, the Bad, and the Incidental: A DGH MDT Review of Lung Cancer Screening	12
Unradical Surgery for Locally-Advanced Thymoma: Is it time to evolve Perspectives?	12
166 Dysphagia and dysphonia screening in lung cancer patients: A scoping review	12
Environmental asbestos exposure and lung cancer	12
209 Final report of two interventions to reduce the risk of death from Pneumocystis pneumonia in patients receiving radical radiotherapy for lung cancer	12
246 Screening 100: Impact of a full roll-out of lung cancer screening on population-level stage shift and modelled survival in North Central London	12
Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition	12
286 Patient Experience of a Hybrid Human–Digital Smoking Cessation Programme Embedded Within the Thoracic Surgical Pathway: A Qualitative Study from Project MURRAY	12
Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer	12
129 Multicentre real-world HER2 (ERBB2)-positive lung adenocarcinoma across two UK tertiary centres: testing rates and clinicopathological characterisation	12
Asbestos-Related lung Cancer: An underappreciated oncological issue	12
Spatiotemporal distribution of mediastinal neoplasms: A comprehensive multi-center study	12
18 The impact of radiology reporting delays on lung cancer care: A single centre experience	11
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma	11
254 Quality of life after radiotherapy treatment for patients with stage IV non-small cell Lung cancer: QUARTZ LUNG a Candidate-Specific Trial within the TOURIST Platform	11
ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report	11
114 The role of the Patient Cancer Care Coordinator in the Lung Cancer Pathway – reducing health inequalities and optimising patient access	11
Lung cancer caused by asbestos: What a reporting pathologist needs to know	11
118 Occupational causes of respiratory cancers: Current and emerging trends and promoting prevention	11
86 Does entering clinical trials achieve better survival outcomes compared to standard of care in metastatic non-small cell lung cancer patients	11
Impact of N1 lymph node burden on survival outcomes in non-skip pN2 non-small-cell lung cancer	11
57 Real-world insights from the ctDNA transformation pilot funded by NHS England for patients with advanced non-small cell lung cancer (NSCLC) in South East England	11
132 A review of why patients with performance status 0-2 didn't receive anti-cancer treatment	11
33 Implementation of a Lung Oncology Virtual Ward (VW) – Accelerating Responsiveness to Personalised Care Management	11
9 Evaluating outcomes in a district general hospital pleural service	11
51 Percutaneous tissue sampling in thoracic oncology - are core biopsies bigger and better?	11
182 Lung cancer findings from two Targeted Lung Health Check programmes running simultaneously across different geographically close regions and NHS trusts	11
257 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma	11
227 CT Characteristics in Small Cell Lung Cancer: Prognostic Markers and Paraneoplastic Syndrome Associations	11
109 Developing the role of the Lung Cancer Nurse Specialist (CNS) to support wider Clinical Practice beyond traditional role boundaries	11
174 The prevalence and clinical outcomes of incidental thymic lesions detected through Lung Cancer Screening	11
PRIMALung (EORTC-1901-LCG): prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients	10
Corrigendum to “Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre” [Lung Cancer 211 (2026) 108	10
T cell immunity in interstitial lung disease with non-small cell lung cancer patients	10
Outcome of stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer (NSCLC)	10
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression	10
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non–small cell lung cancer	10
198 Clinical Outcomes of Stereotactic Ablative Radiotherapy (SABR) for Primary Lung Cancer in Older Patients: Royal Free London Experience	10
74 Heterogeneity and High Cancer Conversion in a Real-World Pulmonary Nodule Cohort: Implications for UK Surveillance Practice	10
Contents	10
Adjuvant immunotherapy after concurrent chemoradiation for locally advanced NSCLC: audit from Northern Ireland	10
Impact of perioperative fluids on clinical outcomes following thoracic surgery: a single-centre propensity matched retrospective study	10
Association between surgical quality and long-term survival in lung cancer	10
Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report	10
156 Monitoring and management of cardiovascular complications in patients receiving tyrosine kinase inhibitors for lung malignancy	10
Revisiting the lung cancer screening eligibility criteria to promote equity for Black individuals	10
Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy	10
Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma	10
273 Lung cancer care after a best supportive care diagnosis: what are we missing?	10
84 Optimising Sampling Strategies in the Diagnosis of Pulmonary Nodules	10
Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges	10
Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 81	10
The issue of no tissue: lung cancer patients without a tissue diagnosis in NHS Lothian	10
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma	10
EBUS audit: assessing the diagnostic performance of the service at UHL	10
Hamlet.rt Trans: a prospective single-centre translational sub-study evaluation of liquid biomarkers of radiation response	10
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC	10
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study	10
76 BTOG Large Cell Neuroendocrine Carcinoma Special Interest Group: Interim feasibility analysis froma national multicentre digital pathology review of diagnostic consensus	10
Type of lymphadenectomy does not influence survival in pIa NSCLC patients who underwent VATS lobectomy: Results from the national VATS group database	10
Occupational asbestos exposure and survival among lung cancer patients	10
Implementing adjuvant immunotherapy following radical chemoradiotherapy for stage III non-small cell lung cancer in UK clinical practice: are the PACIFIC trial outcomes achievable in the real world?	10
Editorial Board	10
Genomic landscape of stage 0–IA lung adenocarcinoma identified by on-site reflex targeted NGS	10